

**TABLE 2a Kaplan Meier survival estimates. Probability to remain responders**

**TABLE 2b Kaplan Meier survival estimates. Probability of continuing STP with no-change in treatment schedule**

TABLE 2a		% Responders (CI 95%)							p-value
		6 months	12 months	24 months	48 months	60 months	120 months	240 months	
	<b>All patients</b>	81.1 (71.7-87.7)	68.2 (57.5-76.8)	61.1 (49.8-70.6)	44.7 (32.8-55.9)	41.5 (29.1-53.5)	32.3 (18.3-47.1)	32.3 (18.3-47.1)	
	<b>By duration of epilepsy</b>								0.3785
	<i>≤ 60 months</i>	79.6 (65.4-88.5)	77.4 (62.8-86.9)	72.1 (56.5-82.9)	50.3 (33.2-65.2)	44.7 (26.7-61.3)	26.8 (8.6-4.94)	26.8 (8.6-4.94)	
	<i>&gt; 60 months</i>	82.8 (68.5-91.0)	57.8 (41.3-71.1)	48.6 (32.2-63.2)	38.3 (22.3-54.1)	38.3 (22.3-54.1)	38.3 (22.3-54.1)	.	
	<b>By focal seizure types*</b>								0.2939
	<i>Focal</i>	68.7 (40.5-85.6)	68.7 (40.5-85.6)	49.1 (20.3-72.8)	49.1 (20.3-72.8)	32.7 (6.7-63.0)	.	.	
	<i>SGS</i>	72.9 (27.6-92.5)	72.9 (27.6-92.5)	72.9 (27.6-92.5)	72.9 (27.6-92.5)	72.9 (27.6-92.5)	.	.	
	<b>By generalized seizure types**</b>								0.2942
	<i>GTCS</i>	68.7 (40.5-85.6)	61.9 (33.9-80.8)	61.9 (33.9-80.8)	30.9 (8.2-57.7)	30.9 (8.2-57.7)	.	.	
	<i>Others</i>	93.3 (75.9-98.3)	67.7 (47.0-81.7)	62.9 (41.5-78.2)	57.6 (35.9-74.3)	57.6 (35.9-74.3)	28.8 (5.7-58.2)	28.8 (5.7-58.2)	
	<b>By epilepsy types</b>								0.9294
	<i>Focal</i>	70.3 (47.5-84.6)	70.3 (47.5-84.6)	57.5 (33.1-75.8)	57.5 (33.1-75.8)	46.0 (19.3-69.3)	.	.	
	<i>Generalized</i>	84.6 (70.3-92.3)	65.54 (49.4-77.6)	62.42 (45.9-75.2)	48.5 (31.3-63.8)	48.5 (31.3-63.8)	29.1 (9.6-52.3)	29.1 (9.6-52.3)	
	<i>Combined</i>	85.3 (65.3-94.2)	72.8 (51.1-86.1)	63.6 (41.3-79.4)	33.6 (14.9-53.5)	33.6 (14.9-53.5)	.	.	
	<b>Structural</b>	85.7 (62.0-95.2)	63.7 (38.2-80.9)	63.7 (38.2-80.9)	45.5 (19.3-68.6)	30.3 (6.5-59.4)	.	.	0.0321
	<b>Unknown</b>	77.2 (58.0-88.4)	62.2 (42.0-77.2)	48.9 (28.8-66.3)	44.5 (25.0-62.3)	44.5 (25.0-62.3)	.	.	

	<i>Immune infective</i>	33.3 (0.9-77.4)	.	.	.	.	.	.	
	<i>Dravet syndrome</i>	95.6 (72.9-99.4)	90.9 (68.1-97.6)	90.9 (68.1-97.6)	57.9 (32.8-76.5)	57.9 (32.8-76.5)	41.3 (17.2-64.2)	41.3 (17.2-64.2)	
	<i>Other genetic</i>	72.7 (46.3-87.6)	61.0 (35.0-79.2)	45.7 (20.3-68.1)	36.6 (13.1-60.8)	36.6 (13.1-60.8)	.	.	
<b>By concomitant AED number</b>	$\leq 2$ AEDs	84.0 (72.9-90.8)	67.1 (54.4-77.0)	57.9 (44.7-69.1)	40.6 (27.3-53.6)	40.6 (27.3-53.6)	34.9 (20.0-50.2)	34.9 (20.0-50.2)	0.8800
	$> 2$ AEDs	72.5 (50.7-85.8)	72.5 (50.7-85.8)	72.5 (50.7-85.8)	55.2 (28.2-75.7)	36.8 (8.2-67.1)	.	.	

<b>TABLE 2b</b>		<b>% Responders (CI 95%)</b>							
		<i>6 months</i>	<i>12 months</i>	<i>24 months</i>	<i>48 months</i>	<i>60 months</i>	<i>120 months</i>	<i>240 months</i>	<i>p</i>
<b>All patients</b>		90.1 (84.4-93.9)	83.6 (76.6-88.6)	70.2 (60.9-77.6)	44.6 (33.4-55.1)	33.2 (22.2-44.6)	10.0 (3.4-20.7)	.	
<b>By duration of epilepsy</b>	$\leq 60$ months	90.6 (82.0-95.2)	84.9 (74.8-91.2)	73.3 (60.3-82.6)	51.5 (35.8-65.2)	41.6 (25.9-56.6)	14.0 (3.8-30.6)	.	0.0310
	$> 60$ months	89.2 (79.5-94.5)	81.0 (69.3-88.6)	65.2 (50.5-76.5)	35.0 (20.0-50.4)	21.9 (9.0-38.3)	6.5 (0.6-23.3)	.	
<b>By focal seizure types*</b>	<i>Focal</i>	93.1 (75.1-98.2)	88.2 (67.1-96.1)	80.9 (54.4-92.9)	71.9 (41.7-88.3)	47.9 (16.8-73.8)	.	.	0.8359
	<i>SGS</i>	90.4 (66.8-97.5)	78.4 (51.7-91.4)	78.4 (51.7-91.4)	26.1 (1.1-66.9)	26.1 (1.1-66.9)	.	.	
<b>By generalized seizure types**</b>	<i>GTCS</i>	86.2 (67.2-94.6)	74.6 (53.7-87.1)	47.6 (26.7-65.8)	26.8 (8.9-49.3)	17.8 (3.5-41.2)	.	.	0.1888
	<i>Others</i>	83.9 (67.5-92.4)	80.6 (63.5-90.3)	72.9 (53.6-85.1)	43.7 (23.4-62.4)	33.3 (15.0-52.9)	16.6 (4.4-35.9)	.	

<b>By epilepsy types</b>	<i>Focal</i>	91.9 (79.7-97.0)	83.5 (68.0-91.9)	78.3 (59.2-89.2)	58.7 (34.0-76.9)	41.9 (17.6-64.7)	.	.	0.5623
	<i>Generalized</i>	84.9 (73.7-91.6)	78.1 (65.7-86.4)	60.9 (46.3-72.6)	36.0 (21.6-50.7)	26.7 (13.8-41.5)	13.3 (4.4-27.2)	.	
	<i>Combined</i>	95.8 (84.1-99.0)	91.0 (77.8-96.6)	77.6 (59.5-88.4)	48.9 (27.5-67.4)	40.8 (18.9-61.7)	.	.	
<b>By etiology</b>	<i>Structural</i>	92.9 (79.5-97.7)	86.7 (70.6-94.3)	62.9 (37.0-80.6)	52.4 (24.5-74.4)	35.0 (7.6-65.2)	.	.	0.0324
	<i>Unknown</i>	86.2 (73.2-93.2)	79.3 (64.7-88.3)	69.7 (52.7-81.6)	25.4 (10.8-43.0)	15.9 (4.6-33.2)	.	.	
	<i>Metabolic</i>	.	.	.	.	.	.	.	
	<i>Dravet syndrome</i>	91.7 (76.5-97.3)	88.8 (72.8-95.6)	79.2 (61.2-89.6)	63.0 (42.4-78.0)	53.3 (32.3-70.5)	23.7 (6.6-4.6)	.	
	<i>Immune infective</i>	100	75.0 (12.8-96.0)	.	.	.	.	.	
	<i>Other genetic</i>	88.3 (67.9-96.1)	79.6 (57.5-91.0)	66.1 (40.0-83.0)	43.4 (14.34-69.8)	21.7 (1.4-57.6)	.	.	
<b>By concomitant AED number</b>	$\leq 2$ AEDs	93.2 (86.8-96.5)	89.1 (81.6-93.7)	74.7 (63.6-82.9)	48.3 (34.4-60.8)	32.9 (19.2-47.3)	13.2 (3.8-28.4)	.	02.44.00
	$> 2$ AEDs	79.8 (63.4-89.4)	63.4 (45.0-77.1)	52.2 (33.5-67.9)	33.8 (16.6-52.0)	33.8 (16.6-52.0)	.	.	

SGS= secondarily generalized seizures; GTCS= generalized tonic-clonic seizures; AEDs: antiepileptic drugs; \* Patients with focal epilepsy only; \*\* Patients with generalized epilepsy only.